# What We Heard at PDA Week 2026: A Data-Driven Session Analysis Source: https://www.globalkeysolutions.net/media/pda-week-2026-session-analysis/ Type: blog Published: March 27, 2026 Authors: George Kwiecinski, Zephaniah Odidika > GKS analyzed sessions attended at PDA Week 2026 in Denver. See what AI, quality, and regulatory terms dominated — and what it means for pharma in 2026. --- *A short analysis of the sessions attended by [George Kwiecinski](https://www.linkedin.com/in/kwiecinskigeorge/) and [Zephaniah Odidika](https://www.linkedin.com/in/zcco/) at [PDA Week 2026](https://www.pda.org/global-event-calendar/event-detail/pda-week-2026) in Denver, CO, March 22-27, 2026.* --- ![download-2.jpg](https://storage.googleapis.com/gks-blog-images/blog-images/cf3318504f934b33a7caa1dbb63a3696.jpg) --- ## Purpose [George](https://www.linkedin.com/in/kwiecinskigeorge/) and [Zeph](https://www.linkedin.com/in/zcco/) attended [PDA Week 2026](https://www.pda.org/global-event-calendar/event-detail/pda-week-2026) focused specifically on AI and quality-adjacent sessions, to assess how well industry conversation aligns with what we are building at [KeyPedia](https://www.globalkeysolutions.net/platform/overview) and [GKS](https://www.globalkeysolutions.net). --- ## Methods We took the text descriptions of each session we attended at [PDA Week](https://www.pda.org/global-event-calendar/event-detail/pda-week-2026) and ran keyword frequency and cluster analysis across them. No transcripts, recordings, or slides, only session abstracts as a clean, unbiased signal of what topics were on the table at the [Parenteral Drug Association](https://www.pda.org)'s premier annual event. --- ## Results ![pda_keyword_analysis_scientific (1).png](https://storage.googleapis.com/gks-blog-images/blog-images/43b2e2480c8a41cab3cfdea4f63b5f25.png) *Keyword frequency across attended sessions (n=23), grouped by thematic domain.* ![pda_cluster_analysis.png](https://storage.googleapis.com/gks-blog-images/blog-images/5e5d6a6f7966450293be6695a254efe7.png) *Topic cluster analysis of attended sessions via TF-IDF, PCA, and K-Means (k=6) -- six distinct thematic groupings across 23 sessions.*
As confirmed, our session selection aligned tightly with our interests. AI, Quality, and Regulatory were by far the most cited terms across everything we attended. Three things stand out from the data: - **Frequency followed an exponential decay curve.** AI and Quality dominated heavily, with a long tail of supporting concepts including [Data Integrity](https://link.springer.com/article/10.1007/s12247-026-10406-3), GMP, and Supply Chain Risk. - **Digital transformation and AI terms clustered tightly.** "Data," "analytics," "automation," and "digital" moved together, confirming these are no longer separate conversations in pharma quality. - **Human factors showed up more than expected.** Behavioral science, training, workforce, and culture surfaced as a meaningful secondary cluster, reflecting the industry's recognition that technology alone does not drive compliance. --- ## Discussion We will post our full session notes and takeaways in the near term. Three takeaways are already clear: **1. The maturity curve on AI in pharma has shifted.** Education, case studies, and honest reflection around AI projects has substantially increased. The conversation has moved from "should we?" to "how do we govern it responsibly?" [PDA Technical Reports](http://pda.org/publications/pda-technical-reports), including TR80 on Data Integrity and TR84 on Manufacturing Data Integrity, provide useful context as the regulatory framework continues to evolve. **2. The [PDA Whiteboard](https://www.pda.org/document-review/document-rating) is worth watching.** This new [PDA](https://www.pda.org) program lets practitioners rate and surface what matters most in the document review landscape. Continuous advancement driven by practitioners, not just institutions, is exactly what the industry needs. **3. It is exciting to see [PDA](https://www.pda.org) adopting mediums beyond the traditional lecture format.** Posters, workshops, and working groups are exactly what continued advancement in pharma AI and quality systems requires, and [PDA Week 2026](https://www.pda.org/global-event-calendar/event-detail/pda-week-2026) showed real momentum in that direction. --- ## What's Next Full notes and session takeaways coming shortly. In the meantime, explore [KeyPedia](https://www.globalkeysolutions.net/platform/overview), our AI-powered regulatory intelligence platform, or read our peer-reviewed research on [FDA GMP inspection trends](https://link.springer.com/article/10.1007/s12247-026-10406-3), published in the [Journal of Pharmaceutical Innovation](https://link.springer.com/article/10.1007/s12247-026-10406-3) (Springer Nature, 2026). You can also browse [KeyPedia Lite](https://www.globalkeysolutions.net/browse) for free access to our regulatory data, or [request a demo](https://www.globalkeysolutions.net/request-demo) to see the full platform. Follow [GKS on LinkedIn](https://www.linkedin.com/company/globalkeysolutions/) for the full PDA Week debrief. --- *Note: This analysis reflects only the sessions attended by [George](https://www.linkedin.com/in/kwiecinskigeorge/) and [Zeph](https://www.linkedin.com/in/zcco/). It is not a full-conference analysis. Session selection was intentional and focused on AI and quality-adjacent tracks at [PDA Week 2026](https://www.pda.org/global-event-calendar/event-detail/pda-week-2026).*